Market Currents

• Tuesday, May 26, 2009

• 09:01 AM Premarket gainers: MAPP +138%. CYTK +46%. BNC +15%. CPST +13%. HEB +12%. OXGN +9%. UTHR +8%. FEED +7%. Q +6%. ALTI +5%. ARNA +4%.
  Losers: TMS +13%. CIM -10%. AIB -7%. GM -6%. CSIQ -6%. FSLR -5%. AIG -5%. DNN -5%. VE -4%. Comment!

• Monday, March 16, 2009

• 09:00 AM Premarket losers: UTHR -10%. ITW -7.8%. SNDK -7%. FLR -5%. MGM -5%. CVTX -5%. Comment!

• Monday, November 17, 2008

• 09:27 AM JPMorgan defends its Overweight rating of United Therapeutics (UTHR) despite the failure of the phase III FREEDOM-C trial to meet its primary goal. Deutsche drops to Hold with a $70 target. Barclays defends a Buy and a $137 target. Shares -33% to $60.25. Comment!
• 08:53 AM Premarket losers: UTHR -29.4%. RBS -9.8%. MTL -9.5%. AEG -8.5%. CF -8.2%. BIDU -7.2%. HD -6.5%. HIG -6.25%. TGT -5.7%. FCX -5.5%. DELL -5.3%. YGE -5.3%. JASO -4.6%. AA -4.5%. GS -4.2%. ING -4%. AUY -4%. AMZN -3.8%. Comment!

• Sunday, August 17, 2008

• 07:01 AM Big Pharma is feeling the need to find new products with blockbuster potential as important patents expire. Likely buyout targets include AMLN, UTHR, ALXN. ONXX and VRTX, Barron's says. Comment!